![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sunesis Pharmaceuticals Inc | NASDAQ:SNSS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.32 | 4.72 | 4.75 | 0 | 01:00:00 |
“We are grateful for all those working so hard to address the current COVID-19 pandemic. As we navigate our business challenges associated with the pandemic, we continue to make progress on both our vecabrutinib and SNS-510 programs. We still expect initial response assessments for the 500 mg cohort in our Phase 1b/2 study of vecabrutinib this quarter, as well as follow up assessments from patients from lower dose cohorts who remain on treatment. For our first-in-class PDK1 inhibitor, SNS-510, we remain on track to file an IND by year end,” said Dayton Misfeldt, Interim Chief Executive Officer of Sunesis. “Going forward, there is potential for delays in vecabrutinib development due to impact on sites. We will assess next steps and provide updates as data from the Phase 1b portion of the trial emerge and the COVID-19 situation evolves.”
Vecabrutinib Phase 1b/2 Clinical Update. Sunesis continues to follow patients enrolled in cohorts 5-7 of the ongoing Phase 1b/2 trial. Vecabrutinib has been very well tolerated in the higher dose levels.
SNS-510, first-in-class PDK1 inhibitor. We continue to make progress in our IND-enabling program for the oral PDK1 inhibitor, SNS-510. SNS-510 inhibits both PI3K signaling and PIP3-independent pathways integral to many malignancies. Preclinical studies revealed that CDKN2A-mutated tumors are particularly sensitive to SNS-510. CDKN2A alterations are common in human cancers and may prove to be useful biomarkers for broad investigation of SNS-510 as a monotherapy and in combination with other anticancer agents. We are on track to file an IND by the end of 2020 and expect to present preclinical findings in the second half of the year.
Promoted Tina Gullotta to VP, Finance. Ms. Gullotta joined Sunesis in August 2018 with extensive experience in accounting, finance, and investor relations in the biotech industry. Prior to joining the company, Ms. Gullotta was the Corporate Controller and held various other management positions at Atara Biotherapeutics, Inc. a public immunotherapy company. Prior to joining Atara Biotherapeutics, Inc., Ms. Gullotta held financial management positions in various industries including retail and telecommunications, and began her career in the business assurance practice with PricewaterhouseCoopers LLP. Ms. Gullotta received a B.S.C. in Accounting from Santa Clara University.
Financial Highlights
Conference Call Information
Sunesis will host a conference call today at 4:30 p.m. Eastern Time. The call can be accessed by dialing (844) 296-7720 (U.S. and Canada) or (574) 990-1148 (international) and entering passcode 6168259. To access the live audio webcast, or the subsequent archived recording, visit the “Investors and Media – Calendar of Events” section of the Sunesis website at www.sunesis.com. The webcast will be recorded and available for replay on the company’s website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, including its oral non-covalent BTK inhibitor vecabrutinib and first-in-class PDK1 inhibitor SNS-510. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies that have progressed after prior therapies.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to Sunesis’ continued development of vecabrutinib, including the timing and results of the Phase 1b/2 trial of vecabrutinib and the therapeutic potential of vecabrutinib, further development and potential of its kinase inhibitor pipeline; the timing of the potential IND filing for SNS-510; Sunesis’ ability to receive potential milestone or royalty payments under license and collaboration agreements and the timing of receipt of those payments; the sufficiency of Sunesis’ cash resources and financial position; and the effect the COVID-19 pandemic may have on any of the foregoing. Words such as “expect,” “will,” “look forward,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" in Sunesis' Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 and Sunesis' other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Sunesis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
SUNESIS PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except per share amounts)
Three months endedMarch 31, | |||||||
2020 | 2019 | ||||||
(Unaudited) | |||||||
Revenue: | |||||||
License and other revenue | $ | 120 | $ | — | |||
Total revenues | 120 | — | |||||
Operating expenses: | |||||||
Research and development | 3,690 | 3,248 | |||||
General and administrative | 2,228 | 2,439 | |||||
Total operating expenses | 5,918 | 5,687 | |||||
Loss from operations | (5,798 | ) | (5,687 | ) | |||
Interest expense | (70 | ) | (261 | ) | |||
Other income, net | 93 | 88 | |||||
Net loss | (5,775 | ) | (5,860 | ) | |||
Unrealized loss on available-for-sale securities | (1 | ) | — | ||||
Comprehensive loss | $ | (5,776 | ) | $ | (5,860 | ) | |
Basic and diluted loss per common share: | |||||||
Net loss | $ | (5,775 | ) | $ | (5,860 | ) | |
Shares used in computing net loss per common share | 111,393 | 59,142 | |||||
Net loss per common share | $ | (0.05 | ) | $ | (0.10 | ) |
SUNESIS PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
March 31,2020 | December 31,2019 | ||||||
(Unaudited) | (1) | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 19,974 | $ | 12,761 | |||
Restricted cash | 5,500 | 5,500 | |||||
Marketable securities | 3,445 | 16,364 | |||||
Prepaids and other current assets | 1,790 | 1,697 | |||||
Total current assets | 30,709 | 36,322 | |||||
Property and equipment, net | 1 | 3 | |||||
Operating lease right-of-use asset | 681 | 817 | |||||
Other assets | 96 | 98 | |||||
Total assets | $ | 31,487 | $ | 37,240 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 862 | $ | 791 | |||
Accrued clinical expense | 600 | 521 | |||||
Accrued compensation | 746 | 985 | |||||
Other accrued liabilities | 1,039 | 1,109 | |||||
Notes payable | 5,469 | 5,465 | |||||
Operating lease liability - current | 545 | 545 | |||||
Total current liabilities | 9,261 | 9,416 | |||||
Other liabilities | 4 | 9 | |||||
Operating lease liability - long term | 136 | 272 | |||||
Total liabilities | 9,401 | 9,697 | |||||
Commitments and contingencies | |||||||
Stockholders’ equity: | |||||||
Convertible preferred stock | 11,769 | 11,769 | |||||
Common stock | 11 | 11 | |||||
Additional paid-in capital | 698,881 | 698,562 | |||||
Accumulated other comprehensive income | — | 1 | |||||
Accumulated deficit | (688,575 | ) | (682,800 | ) | |||
Total stockholders’ equity | 22,086 | 27,543 | |||||
Total liabilities and stockholders’ equity | $ | 31,487 | $ | 37,240 |
(1) The condensed consolidated balance sheet as of December 31, 2019, has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
Investor and Media Inquiries: Maeve Conneighton Argot Partners 212-600-1902 | Par Hyare Sunesis Pharmaceuticals Inc. 650-266-3784 |
1 Year Sunesis Pharmaceuticals Chart |
1 Month Sunesis Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions